Evaluation and Treatment of Hypotension in Premature Infants by Shoichi Ezaki & Masanori Tamura
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Evaluation and Treatment  
of Hypotension in Premature Infants 
Shoichi Ezaki and Masanori Tamura 
Division of Neonatal Medicine, Center for Maternal,  
Fetal and Neonatal Medicine, Saitama Medical Center, 
 Saitama Medical University,  
Japan 
1. Introduction 
Sixteen to 98% of extremely preterm infants are treated for hypotension within the first 
week of life. The enormous variation in this estimate is due to a lack of reliable evidence. 
While selecting a vasoactive agent, it is necessary to consider the goals of the therapy. To 
achieve those goals, the clinician must assess the mechanisms of action of the potential 
therapies. This chapter details the unique characteristics of the neonatal cardiovascular 
system and defines hypotension in preterm infants. It provides indications for treatment and 
appropriate therapies for individual cases. 
2. Characteristic pathophysiology of hypotension in preterm infants 
Blood pressure increases with advancing gestational and postnatal age, which is a 
developmentally regulated phenomenon (Noori and Seli, 2005). Since cardiac output (CO) 
and systemic vascular resistance (SVR) both contribute to blood pressure, elevation in blood 
pressure during development may be the result of increased CO, increased SVR, or both 
(Fig.1) 
2.1 Hypovolemia 
In preterm infants, absolute hypovolemia is the most frequent cause of hypotension. 
Peripheral vasodilation with or without myocardial failure is the most frequent primary 
etiological factor (Seli and Evans J, 2001). Absolute hypovolemia is defined as a loss of 
volume from the intravascular compartment; alternatively, relative hypovolemia is defined 
as vasodilatation with an inadequate volume to fill the expanded intravascular 
compartment. In both situations, the result is inadequate filling pressure (also known as 
preload) in the heart. If severe enough, hypovolemia can reduce CO, resulting in inadequate 
tissue perfusion and oxygenation (Fig 1). 
In cases of absolute hypovolemia, the body releases corticosteroids, adrenaline, and 
noradrenaline, which cause vascular contraction in order to maintain blood pressure and 
filling pressure and cause increased heart rate and contractility to maintain systemic blood 
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flow (SBF). However, in sick or immature infants, this response may be limited (Ng et al., 
2001; Evans N, 2003). In addition, volume administration for the treatment of hypotension in 
sick infants has been reported to have a dopaminergic effect (Seli and Evans J, 2001).  
In preterm infants with acute blood loss (e.g., intraventricular hemorrhage [IVH]) or 
excessive transepidermal water losses (e.g., gestational age ≤ 25 weeks), absolute 
hypovolemia should be considered the primary cause of hypotension. 
 
Fig. 1. Mechanism of preterm hypotension 
2.2 Myocardial dysfunction 
Myocardial contraction and relaxation depend on the regulation of cytosolic calcium 
concentration and the responsivity of myofilaments to changes in calcium content. Preterm 
infants, term infants, and adults all have the membrane systems that control cell calcium 
flux and the sarcomeres that make up the myofibrils. However, the components of each 
system undergo qualitative and quantitative changes during development. During in the 
prenatal and newborn periods, myocytes change in size and shape. There are also changes 
in the number of contractile elements and the nuclear-to-cellular volume ratio. 
Cardiac contraction is an energy-dependent process that requires ATP, calcium, and an 
ATPase located at the myosin head. The processes of contraction and relaxation in immature 
myocardium as well as calcium homeostasis are different from those in mature 
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myocardium. Specifically, immature myocytes do not rely as heavily on the release and re-
uptake of calcium from the sarcoplasmic reticulum; instead, they depend more on 
extracellular calcium concentration. As such, the immature myocardium of the fetus and 
newborn depends on L-type calcium channels as a calcium source for contraction. 
Furthermore, immature myocytes have greater cell surface area-to-volume ratios, which 
may compensate for their underdeveloped T-tubule systems. The alterations in myocardial 
structure and function with maturation and the developmental changes in cardiovascular 
function provide the cellular and molecular bases for differences in myocardial contractility 
among preterm newborns, term newborns, and older infants (Rowland and Gutgesell, 1995; 
Noori and Seli, 2005). 
Therefore, preterm infants with hypotension have a limited ability to increase CO in 
response to inotropes or changes in volume (Teitel and Sidi, 1985). Furthermore, they have 
an elevated sensitivity to increased afterload (Van Hare et al., 1990), which commonly leads 
to decreased CO (Belik and Light, 1989). 
2.3 Abnormal peripheral vasoregulation 
Immediately after birth, there is a sudden increase in SVR. This can have a deleterious effect 
on CO and potentially compromise organ blood flow. After the initial transition period, 
vasodilation predominates rather than vasoconstriction. Indeed, the complex regulation of 
vascular smooth muscle tone involves a delicate balance between vasodilators and 
vasoconstrictors (Fig. 1 and Fig. 2).  
hANP: human atrial natriuretic peptide, NO: Nitric oxide, GTP: guanosine triphosphate, 
cGMP: cyclic guanosine monophosphate 
The endogenous vasodilating factors include NO, eicosanoids, hAMP, and endothelin. The 
endogenous vasoconstrictive factors include catecholamines, vasopressin, and angiotensin 
II. The balance of these factors determines the blood vessel equilibrium and the tendency 
toward vasodilation or vasoconstriction (Fig.2). In Figure 2, the vasoconstriction pathway is 
shown in red, and the vasodilatation pathway is shown in blue. Phosphorylation of myosin 
is the critical step in vascular smooth muscle contraction. Vasoconstrictors, such as 
angiotensin II, vasopressin and norepinephrine, activate second messengers to increase 
cytosolic calcium concentration, which in turn activates myosin light chain kinase. 
Vasodilators, such as human atrial natriuretic peptide (hANP) and nitric oxide (NO), 
activate myosin phosphatase, which dephosphorylates myosin to cause vasorelaxation. The 
plasma membrane is shown at its resting potential (plus signs). cGMP denotes cyclic 
guanosine monophosphate (Landry and Oliver, 2001). In addition, potassium channels in 
the smooth muscle cell membrane have recently been implicated in the pathogenesis of 
vasodilatory shock (Liedel et al., 2002). 
Under normal physiologic conditions, CO remains essentially unchanged throughout 
infancy. Therefore, the increased blood pressure with advancing gestational and postnatal 
age is primarily the result of increased SVR. Maturation of vascular smooth muscle, changes 
in the expression of vascular angiotensin II receptor subtypes, and maturation of the central 
autonomic and peripheral nervous systems play significant roles in increasing vascular tone 
and SVR. There are 2 major subtypes of angiotensin II receptors. AT1R, which is expressed in 
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mature tissues and the umbilical artery, mediates smooth muscle contraction and regulates 
fluid and electrolyte balance. AT2R, which is expressed in fetal and newborn tissues, has an 
unknown function. The developmentally regulated transition from expression of AT2R to 
AT1R begins following the first 2 weeks of life and is complete by month 3 (Noori and Seli, 
2005; Engle, 2001). The vasodilating factor NO increases under conditions of oxidative stress 
and sepsis. Because preterm infants are prone to these conditions (Ezaki et al., 2009a), their NO 
levels can easily increase. Together, these physiological characteristics of preterm infants make 
them susceptible to vasoregulatory dysfunction.  
 
Fig. 2. Regulation of vascular smooth muscle tone  
3. The significance of hypotension requiring treatment in preterm infants  
3.1 Clinical outcomes 
Hypotension is a common complication among preterm infants. Importantly, there is an 
association between systemic hypotension and neonatal morbidities, including IVH and 
neurodevelopmental disorders (Watkins et al., 1989; Goldstein et al., 1995). Unfortunately, 
www.intechopen.com
 Evaluation and Treatment of Hypotension in Premature Infants 
 
423 
common conditions among preterm infants, such as sepsis, renal failure, and neonatal 
asphyxia, can lead to the development of clinical hypotension and confer a poor prognosis.  
3.2 Relationship between systemic blood flow and blood pressure 
The most important goal in treating hypotension is to prevent cellular and tissue damage 
resulting from hypovolemia. Seli et al. and Greisen et al. have reported important 
considerations for the treatment of hypotension (Seli, 2006; Greisen, 2005). If effective 
treatment is not promptly initiated, the blood pressure may decrease further to the 
“ischemic threshold, which is said to be about 30 mmHg,” resulting in tissue ischemia and 
permanent organ damage. For example, a loss of cerebral blood flow (CBF) triggers 
abnormal cerebral function and, finally, tissue ischemia (Fig. 3). Furthermore, high blood 
pressure is also deleterious. Although, exact value is not noted in existing reports, when 
blood pressure exceeds “intraventricular hemorrhage (IVH) threshold”, risk of IVH 
increases (Fig. 3). 
Loss of vascular autoregulation has not been formally proven as a cause of increased 
morbidity and mortality in preterm infants (McLean et al., 2008). However, it has 
consequences that negatively affect prognosis. For instance, loss of autoregulation often 
triggers IVH. In addition, the amount of blood shunted through the patent ductus arteriosus 
(PDA), present in preterm infants, can become unstable. Furthermore, the patient is likely to 
develop necrotizing enterocolitis (NEC) due to compromised blood flow to gastrointestinal 
tract. Finally, once the patient enters the ischemic stage, there is an increased incidence of 
periventricular leukomalacia (PVL) and severe renal failure. As such, although the exact 
reference blood pressure values that cause failure of autoregulation and CBF remain 
unclear, it is important that hypotension be treated properly. 
 
Fig. 3. Proposed relationship between blood flow and mean blood pressure in the cerebral 
circulation of the preterm infant  
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4. Definitions of normotension and hypotension in the preterm infant 
Most preterm infants admitted to the neonatal intensive care unit (NICU) have medical 
conditions, such as respiratory disorders, electrolyte abnormalities, or neonatal asphyxia. In 
addition, because there is a wide range of ages and body weights, it is difficult to define 
hypotension as a single value in preterm infants. A neonate is considered to be hypotensive 
if the mean blood pressure is below the fifth or tenth percentile of the normative data 
according to gestational and postnatal age and weight (Cunningham et al., 1999). Another 
definition of hypotension is a mean blood pressure less than or equal to the patient’s 
gestational age in weeks. Although this definition is a useful tool, it is only valid during the 
first 48 hours of life (Nuntnarumit et al., 1999). However, due to its simplicity, this value is a 
good indicator for neonatologists to suspect hypotension. 
4.1.1 Definition of preterm hypotension and its relationship to low systemic perfusion 
Figure 3 indicates blood pressure values that are thought result from a failure of 
autoregulation. Although they would be an ideal definition of hypotension, no consensus has 
yet been reached. Of preterm infants with a gestational age of 23–26 weeks, >90% have a mean 
blood pressure >30 mmHg (Nuntnarumit et al., 1999). Recent studies suggest that it may be as 
high as 28–30 mmHg, even among extremely low birth-weight infants (Munro et al., 2004). 
4.1.2 Permissive hypotension 
A recent study in very preterm neonates suggested that blood pressure below the clinically-
accepted lower limit during the first postnatal days may not require intervention, as long as 
adequate tissue perfusion is maintained (Dempsey et al., 2009). This study suggested that 
although treatment must be initiated promptly, overzealous treatment may worsen the 
prognosis. Therefore, a diagnosis of hypotension must be based on clinical and laboratory 
findings. 
4.2 Clinical signs  
Many conditions may trigger hypotension in preterm infants (Table 1). The need for tests 
and treatments to prevent decreased tissue perfusion is examined.  
Vasoregulation imbalance 
Hemorrhage: Placental hemorrhage, abruption placenta prevail, feto-maternal hemorrhage, 
birth trauma-subaponeurotic bleed, massive pulmonary hemorrhage. 
Other: Twin-to-twin transfusion, third-space losses, asphyxia, sepsis and septic shock, 
disseminated intravascular coagulopathy, NEC 
Cardiogenic shock 
Asphyxia, electrolyte abnormality, cardiac disease: arrhythmias, congenital heart disease, 
PDA, cardiomyopathy, myocarditis, air leak syndromes 
Endocrine 
Adrenal hemorrhage, adrenal insufficiency   
Drug induced  
Anesthetic drugs, sedative drugs 
Table 1. Causes of hypotension in preterm infants 
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4.3 Hemodynamic monitoring in preterm infants 
An ideal method for monitoring blood pressure would be simple, reliable, non-invasive, and 
painless and would provide continuous measurement. However, such an ideal method has 
not yet been developed. As such, the only reasonable approach to obtaining meaningful 
hemodynamic data in preterm infants is the use of complex, multi-channel, real-time 
monitoring towers combined with streamlined data-acquisition systems and observation of 
clinical symptoms. 
4.3.1 Conventional assessment 
Direct invasive measurements (via umbilical or peripheral artery catheterization) allow for 
constant monitoring of blood pressure in hypotensive preterm infants. Although this 
method is controversial, in our experience, blood pressure values obtained through intra-
arterial catheterization are more accurate than non-intermittent blood pressure 
measurements taken during times of vasoconstriction. In addition, once intermittent blood 
pressure measurements become necessary, the patient’s condition is often already severe, 
making the insertion of an arterial catheter impossible. It is important to note the risks of an 
indwelling catheter, including thrombus formation, hemorrhage, and infection. 
In neonates admitted to the NICU, heart rate is continuously, accurately, and routinely 
monitored. However, factors such as anemia, drugs affecting the cardiovascular system, and 
infection can also affect heart rate. Therefore, heart rate monitoring has a limited role in the 
diagnosis of circulatory compromise. 
Similarly, SpO2 measurements are performed routinely on neonates admitted to the NICU. 
This measures arterial oxygenation as an indicator of the arterial circulation. However, in 
contrast to adults, neonates have unique clinical complications. Clinical oximeters cannot 
detect carbon monoxide hemoglobin, methemoglobin, fetal hemoglobin, or other hemoglobin 
variations. Therefore, blood tests are needed for the accurate assessment a neonate’s 
oxygenation status (Shiao and Ou, 2007). Nevertheless, SpO2 monitors are also useful for 
estimating the extent of the peripheral circulation on the basis of oxygenation waveforms.  
Conventional monitoring of neonatal hemodynamics was restricted to intermittent 
evaluation of indirect clinical and laboratory indices of perfusion, such as peripheral-to-core 
temperature difference, skin color, urine output, capillary refill time, acid-base balance, and 
serum lactate levels. There are limited data available on capillary refill time in preterm 
infants. In the first 24 hours, the use of a capillary refill time of ≥ 3 seconds had a 55% 
sensitivity and 81% specificity for detecting low superior vena cava (SVC) flow (Osborn et 
al., 2004). In addition, abnormalities in skin color, urine output, base excess, and serum 
lactate often arise in other conditions of poor tissue oxygenation. For example, anemia can 
cause skin color abnormalities; kidney disease can cause abnormal urine output; 
dehydration and late metabolic acidosis can exacerbate BE and cause abnormal lactate 
levels. Hence, these measurements are not specific to hypotension and must be assessed in 
combination with other test findings. 
4.3.2 Echocardiography 
Echocardiographic examination may provide useful information regarding CO, contractility, 
pulmonary hemodynamics, and PDA shunting in hypotensive preterm infants. Recently, 
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functional echocardiography has been increasingly used to assess CO, myocardial function, 
and organ blood flow in neonates requiring intensive care (Kluckow et al., 2007). 
4.3.2.1 Systolic performance 
Left ventricular systolic performance can be assessed by measuring the shortening factor 
(SF) and ejection fraction. Normal neonatal values for the SF are 28–40% (El-Khuffash and 
McNamara, 2011). A normal neonatal value for the ejection fraction is approximately 55% 
(Evans N and Kluckow, 1996). 
4.3.2.2 Cardiac output 
Normal left and right ventricular output ranges from 170 to 320 mL · kg-1 · min-1. Low left and 
right ventricular output is defined as < 150 mL · kg-1 · min-1 (normal values range from 170 to 
320 mL · kg-1 · min-1) (Evans N and Kluckow, 1996). Superior Vena Cava Flow (SVC flow) in 
preterm infants is 50–110 mL · kg-1 · min-1. Low SVC flow is defined as below 30 mL · kg-1 · 
min-1 at the first 5 hours post-natally or below 46 mL · kg-1 · min-1 at the first 48 hours 
postnatally (Kluckow, 2005). Approximately 35% of preterm infants of < 30 weeks gestational 
age encounter a period of SVC flow below 40 mL · kg-1 · min-1 during the first 12 hours 
postnatally. After this point, SVC flow typically improves (Kluckow and Evans N, 2000). 
4.3.2.3 Assessment of hypovolemia 
The left ventricular end-diastolic diameter (LVEDD) is used to assess hypovolemia. LVEDD 
is measured at the point of maximal ventricular filling. Normally, the mean LVEDD 
increases from 11 mm at 23–25 weeks, 12 mm at 26–28 weeks, and 13 mm at 29–31 weeks to 
14 mm at 32–33 weeks (Skelton et al., 1998). However, the utility of LVEDD as an indicator 
of hypovolemia in infants has not been systematically examined. In addition to LVEDD, 
other factors can affect left ventricular load in the transitional circulation (Evans N, 2003). 
However, once a preterm infant has been diagnosed with hypovolemia, LVEDD is a useful 
measurement for evaluation.  
Thus, echocardiography is the most suitable test for evaluating cardiac activity and systemic 
perfusion in hypotensive preterm infants. Its drawback is that it does not allow for 
continuous observation. Additionally, there is no evidence that its use is associated with 
better outcomes. Alternatively, ultrasound Doppler, which continuously monitors CO, has 
also been used in neonates (Meyer et al., 2009). 
4.3.3 Assessment of systemic and organ blood flow 
Near-infrared spectroscopy (NIRS) measures hemoglobin flow and venous saturation in the 
forearm to calculate oxygen delivery and consumption and fractional oxygen extraction. In a 
previous study, Nagdyman et al. used NIRS to measure the cerebral tissue oxygenation 
index (TOI), regional cerebral oxygenation index (rSO2), venous oxygen saturation SjO2, 
and central SvO2 from the SVC. They found an association between cerebral TOI and SjO2, 
between cerebral TOI and SvO2, between cerebral rSO2 and SjO2, and between rSO2 and 
SvO2 (Nagdyman et al., 2008). 
Peripheral and mucosal blood flow can be monitored using laser Doppler (Stark et al., 2009; 
Ishiguro et al., 2011), side-stream dark field imaging (Hiedl et al., 2010), and visible light T-
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Sta (Van Bel et al., 2008) technologies. However, these devices have only been used in 
neonates for research purposes.  
4.3.4 Further assessment of hypotension in preterm infants   
As previously described, the diagnosis, treatment determination, and outcome evaluation of 
hypotension must be based on a combination of findings rather than a single marker. If 
possible, a time-course observation can improve the prognosis of hypotensive neonates. 
Soleymani et al. designed a system for hemodynamic monitoring and data collection in 
neonates (Soleymani et al., 2010; Cavabvab et al., 2009). The system integrated conventional 
technologies (i.e., continuous monitoring of heart rate, blood pressure, SpO2, and 
transcutaneous CO2) with novel technologies, including impedance IEC for continuous 
assessment of CO and stroke volume and NIRS to monitor blood flow distribution to the 
brain, kidney, intestine, and/or muscle. 
5. Treatment/ assessment of neonatal hemodynamics during postnatal 
transition 
The first priority in treating hypotensive preterm infants is to maintain hemodynamics 
while the primary etiology is identified and its pathogenesis is addressed. Hemodynamic 
therapy consists of 3 broad categories: fluid resuscitation, vasopressor therapy, and 
inotropic therapy.  
5.1 Fluid bolus 
There is no evidence from randomized trials to support the routine use of early volume 
expansion in very preterm infants with hypotension. Fluid boli are useful in treating 
hypovolemia caused by twin-to-twin transfusion, third-space losses, or hemorrhage. 
However, circulating blood volumes are normal in most hypotensive infants, and there is 
little to no response to volume administration (Bauer et al., 1993). Moreover, preterm infants 
have immature cardiac contractile systems and vascular regulation; as such, volume 
management through fluid boli is not always effective. 
Goldberg et al. observed an increased incidence of IVH among preterm infants receiving 
rapid volume expansion (Goldberg et al., 1980). Additionally, adverse neurological 
outcomes have been reported in preterm infants receiving colloid infusions (Greenough et 
al., 2002). The use of multiple fluid boli is also associated with an increased mortality in 
preterm infants (Ewer et al., 2003). Moreover, the administration of fluid boli has been 
reported be ineffective for cardiopulmonary resuscitation in cases other than at birth 
(Wyckoff et al., 2005). 
There is insufficient evidence to determine the ideal type of volume expansion for preterm 
infants or for early red cell transfusions. Normal saline is equally effective as albumin in 
restoring blood pressure in hypotensive preterm infants. Normal saline is efficacious, safe, 
readily available, and inexpensive; therefore, it has become the fluid of choice for volume 
expansion (Oca et al., 2003). Furthermore, other crystalloids are costly and increase the risk 
of infection and neurodevelopmental deficits (Greenough et al., 2002). 
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5.2 Vasopressors and inotropes 
5.2.1 Catecholamines 
5.2.1.1 Mechanisms of action of catecholamines  
The term “catecholamines” encompasses dopamine (DOA), NE (norepinephrine), and 
epinephrine (E). Catecholamines are produced by adrenal medullary cells and by neurons, 
specifically sympathetic postganglionic neurons. Indeed, adrenal medullary cells can be 
considered a subtype of postganglionic sympathetic neurons. Secretion of catecholamines by 
the adrenal medulla is regulated mainly by acetylcholine released from sympathetic nerve 
endings. 
5.2.1.2 Biosynthesis of catecholamines (Fig.4) 
First, tyrosine is hydroxylated to form dihydroxyphenylalanine (DOPA) in the rate-limiting 
step. DOPA is then converted into DOA through decarboxylation. DOA is packaged into 
secretory granules (chromaffin granules). Dopamine-ǃ-hydroxylase inside the granules 
processes DOA to produce NE. In nerve cells, biosynthesis ends at this stage. In adrenal  
 
 
Fig. 4. Catecholamine biosynthesis 
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medullary cells, NE continues to be processed into E. Once NE is released from the secretory 
granules into the cytoplasm, it is processed by phenylethanolamine-N-methyltransferase 
(PNMT) to form E. E binds to a protein known as chromogranin and is recaptured into 
secretory granules, where it is stored (Goldstein et al., 2003). 
The enzyme PNMT, which catalyzes the transformation of NE into E, is induced by 
glucocorticoids. The direction of blood flow in the adrenal gland travels from the cortex 
toward the medulla; as a result, medullary cells are in contact with the highest levels of 
cortisol. Therefore, E production may be regulated by adrenocortical cells. 
Acetylcholine is secreted from preganglionic neurons upon stimulation of a sympathetic 
nerve. Acetylcholine acts at nicotinic receptors to depolarize chromaffin cells. This opens 
voltage-gated Ca2+ channels, increasing intracellular Ca2+ concentration.This is believed to 
result in the exocytosis of chromaffin granules. 
5.2.1.3 Metabolism of catecholamines 
E and NE secreted from the adrenal medulla are incorporated into various tissues and are 
metabolized by the kidneys. Their half-life in the blood is approximately 2 minutes. They are 
metabolized by 2 enzymes, catecholamine-O-methyltransferase (COMT) and monoamine 
oxidase (MAO), which convert them into metanephrine, normetanephrine, and 
vanillylmandelic acid. In addition to their actions on the heart and blood vessels, 
catecholamines act on the respiratory tract, gastrointestinal tract, urinary tract, sensory 
organs, skeletal muscles, adipose tissues, and pancreatic islets. With glucocorticoids, 
catecholamines also inhibit the proliferation of Th1 cells and promotes their differentiation 
into Th2 cells.  
5.2.1.4 Adrenergic receptors 
The physiological effects of catecholamines are elicited through receptors. The basic 
structure of adrenergic receptors is a seven-transmembrane protein that binds to GTP-
binding proteins. There are 2 major types of adrenergic receptors, ǂ and ǃ, which are further 
classified into subtypes. 
There are 2 major ǂ-adrenergic receptor subtypes, ǂ1 and ǂ2, which are subdivided into 
several pharmacological subtypes. ǂ1 receptors are present at postsynaptic membranes; 
their activation causes contraction of vascular smooth muscles. ǂ2 receptors are present at 
presynaptic membranes and inhibit the release of NE caused by sympathetic stimulation. ǂ2 
receptors are also present in other various cells, such as blood platelets, pancreatic ǃ-cells, 
and adipocytes. ǂ1 receptors activate phospholipase C by conjugating with Gq protein. ǂ2 
receptors act by inhibiting the production of cAMP through inhibitory GTP-binding 
proteins (Gi). 
ǃ-adrenergic receptors are divided into 3 subtypes: ǃ1, ǃ2, and ǃ3. ǃ1 receptors are mainly 
distributed in the heart; ǃ2 receptors are mainly distributed in blood vessels, bronchi, and 
glomerulus, and ǃ3 receptors are mainly distributed in adipocytes. Therefore, ǃ1 receptors 
promote cardiac stimulation; ǃ2 receptors promote bronchodilation, vasodilation, and 
glycogenolysis in muscles, and ǃ3 receptors promote lipolysis. ǃ-adrenergic receptors 
increase the production of cAMP through stimulatory GTP-binding proteins, Gs. This 
activates cAMP-dependent protein kinase A. 
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5.2.1.5 Action of catecholamines 
Catecholamines act through ǂ and ǃ receptors. The catecholamines differ in their action at ǂ 
versus ǃ receptors. For instance, while E acts on ǂ and ǃ receptors, NE acts mainly on ǂ 
receptors (Fig. 5) 
5.2.1.6 Cardiovascular effects of catecholamines 
Through their actions at ǃ1 receptors, catecholamines increase heart rate and cardiac 
contractile force. In coronary arteries, when the ǂ-adrenergic effects of catecholamines 
trigger vasoconstriction, there is a compensatory ǃ2-receptor-mediated vasodilation. In 
general, the vasodilatory effect predominates. Catecholamines also have vasoconstrictive ǂ-
adrenergic effects in arteries of the mucosa, kidney, spleen, and skeletal muscles and in 
venous vasculature. The ǃ-adrenergic vasodilating effects of catecholamines include arterial 
vasodilation due to ǃ2-adrenergic receptors in skeletal muscle. Because of their differential 
effects on adrenergic receptors, each catecholamine differently affects blood pressure and 
blood flow (Fig.6). 
 
 
NE: Nor epinephrine, E: Epinephrine, DOA :Dopamine, DOB:Dobtamine 
Fig. 5. ǂ-and ǃ-Adrenergic receptors effects of vasoactive inotropes  
 
NE: Nor epinephrine, E: Epinephrine, DOA :Dopamine, DOB:Dobutamine 
Fig. 6. Effects of catecholamines on blood pressure and blood flow (partly modified from 
Vincent, 2009)  
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5.2.1.7 Downregulation of adrenergic receptors 
Recently, it has been proposed that exogenous catecholamine administration downregulates 
adrenergic receptors and their associated second-messenger systems (Hausdorff et al., 1999; 
Collins et al., 1991). During receptor downregulation, adrenergic receptors undergo 
lysosomal destruction; therefore, reversal of this process requires new protein synthesis.  
5.2.1.8 Levels of catecholamines in hypotensive preterm infants  
In extremely low birth-weight infants with hypotension, those in need of high doses of 
dopamine (DOA>10μg/kg/min) already had high levels of endogenous dopamine compared 
to those needing low doses of dopamine (DOA <10μg/kg/min) (p<0.05) (Ezaki et al., 2009b). 
The ratio of conversion from NE to E before the use of dopamine and 24 hours after 
administration were correlated in both infants who needed high doses of dopamine and in 
those who did not. This suggested that there was successful conversion of NE to E. In infants 
who did not need high doses of dopamine, there was a similar correlation between conversion 
of DOA to NE before and 24 hours after administration of dopamine. However, no correlation 
was found in infants who needed high doses of dopamine, suggesting that the conversion 
from DOA to NE was limited (Ezaki et al., 2009b) (Fig.7). Therefore, an understanding of the 
underlying pathological condition is important when administering catecholamines. 
 
Fig. 7. Correlations between plasma levels of dopamine and norepinephrine at administration 
(a) and 24 h later (b) and between norepinephrine and epinephrine at administration (c) and 24 
h later (d). The severe hypotension (SH, DOA>10μg/kg/min) group (n = 9) is represented by 
open circles with dotted regression lines, and the mild hypotension (MH, 
DOA<10μg/kg/min) group (n = 13) is represented by closed circles with solid regression lines 
Correlation coefficients and p-values are shown in the respective graphs. 
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5.2.2.1 Treatment of dopamine in preterm hypotension 
Dopamine is the most commonly used vasopressor/inotrope for the treatment of systemic 
hypotension in preterm infants (Seli,1996). DOA stimulates ǂ-adrenergic receptors, ǃ-
adrenergic receptors, and dopaminergic receptors (See 5.2.1.4). DOA stimulates dopamine 
receptors at low doses (0.5 μg · kg-1 · min-1), mainly triggering effects in renal, mesenteric, 
and coronary blood vessels. At doses of 2–4 μg · kg-1 · min-1, DOA acts at ǂ-adrenergic 
receptors, and at doses of 4–8 μg · kg-1 · min-1, DOA acts at ǃ-adrenergic receptors (Seli, 
2006). 
With the exception of E administration, DOA administration is the most effective treatment 
for elevating blood pressure in preterm infants. The increase in CBF following DOA 
administration was found to be greater in hypotensive preterm infants compared to 
normotensive preterm infants, suggesting the presence of pressure-passive CBF in 
hypotensive neonates (Sassano et al., 2011). Therefore, we recommend the use of DOA as a 
first-line inotrope for the treatment of hypotension in preterm infants.  
DOA is also an important neurotransmitter that affects both cerebral vasculature and 
neuronal activity. This is exemplified by pathological conditions caused by dopaminergic 
dysfunction, including abnormalities in CBF and neuronal metabolism (Edvinsson and 
Krause, 2002). In the mature brain, CBF is coupled to oxygen consumption (CMRO2). In 
contrast, CBF coupling to metabolism is strikingly different in the brains of very preterm 
infants, in which cerebral oxygen extraction, not CBF, sustains CMRO2. However, preterm 
infants receiving DOA treatment exhibit flow-metabolism coupling similar to that of the 
mature brain. This suggest a role for DOA in promoting flow-metabolism coupling in the 
preterm brain (Wong et al., 2009). In addition, we previously reported that high-dose 
administration of DOA can limit the conversion of NE to DOA (Ezaki et al., 2009b). 
Therefore, extreme caution must be taken when administering high doses of DOA. 
5.2.2.2 Adverse effects of dopamine treatment 
ǂ2-adrenergic receptors are important in endocrine regulation; as such, even low doses of 
systemically administered DOA have profound endocrine effects. For instance, DOA 
infusion reduces thyroid stimulating hormone and thyroxine levels in very low birth-weight 
infants (Filippi et al., 2004).  
Doses of DOA should rarely exceed 20 μg · kg-1 · min-1, because there is a risk of excessive 
ǂ-adrenergic-receptor-mediated peripheral vasoconstriction and a subsequent reduction in 
CO (Rozé et al., 1993). DOA failed to raise blood pressure in more than 30% of preterm 
infants with systemic hypotension (Pellicer et al., 2005).  
5.2.3 Norepinephrine  
5.2.3.1 The use of norepinephrine in the treatment of preterm hypotension  
NE is a potent vasopressor with ǂ-and, to a lesser extent, ǃ-1 receptor agonist activity 
(Hollenberg et al., 2004). In the adult, NE is primarily used as a vasopressor in states of 
hyperdynamic shock, in which SVR is decreased and mean arterial blood pressure is low 
(Corley, 2004). Experimental studies in fetal lambs have shown that NE may decrease basal 
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pulmonary vascular tone (Houfflin-Debarge et al., 2001) and elevate pulmonary blood flow 
through activating ǂ2-adrenergic receptors and NO release (Magnenant et al., 2003).  
NE can reduce damage incurred by neuroinflammatory and neurodegenerative conditions. 
It induces the expression of the chemokine CCL2 in astrocytes, which is neuroprotective 
against excitotoxic damage (Madrigal et al., 2009). Indeed, early associative somatosensory 
conditioning requires NE (Landers and Sulliyan, 1999). 
Thus, NE plays an important role not only in the cardiovascular system, but also in neonatal 
development. However, there are few studies on the use of NE in the treatment of 
hypotension in preterm infants. While no studies have compared NE to other drugs, its 
therapeutic effects in neonates have recently been reported (Paradisis and Osborn, 2004). 
The use of NE (0.5-0.75 μg · kg-1 · min-1) is effective in the treatment of term and near-term 
infants with septic shock that are resistant to DOA and dobutamine (Tourneux et al., 2008a). 
In neonates with persistent pulmonary hypertension-induced cardiac dysfunction, NE can 
reduce O2 requirements and normalize the systemic artery pressure (Tourneux et al., 2008b).  
5.2.3.2 Adverse effects of norepinephrine treatment 
In all previous reports describing the use of NE in neonates, NE was administered after 
other inotropes, making it impossible to describe the side effects solely attributable to NE. In 
addition, there are no reports on the long-term consequences of the use of NE in preterm 
infants. In general, excessive peripheral vasoconstriction causes a decrease in the contractile 
forces of the immature heart. This may result in tachycardia or decreased tissue perfusion. 
Therefore, capillary refill time, lactate levels, and peripheral and organ blood flow should be 
monitored.  
5.2.4 Epinephrine 
5.2.4.1 The use of epinephrine for the treatment of preterm hypotension 
Low and moderate doses of E (0.125–0.5 μg · kg-1 · min-1) have found to be as effective as 
low and moderate doses of DOA (2.5–10 μg · kg-1 · min-1) for the treatment of hypotension 
in preterm infants (Valverde et al., 2006). In addition, the infusion of E increases mean 
arterial blood pressure and heart rate without decreasing urine output in very low birth-
weight infants with hypotension that do not respond to dopamine infusion up to 15 μg · kg-
1 · min-1 (Heckmann et al., 2002). 
5.2.4.2 Adverse effects of epinephrine 
Compared DOA, E use cases temporary dysfunction of carbohydrate and lactate metabolism 
(Valverde et al., 2006) and increased metabolic acidosis (Heckmann et al., 2002). E directly 
affects lactate metabolism by increasing lactate production and decreasing lactate 
metabolism, thus increasing serum lactate concentrations (Cheung et al., 1997). At very high 
doses, E induces vasoconstriction sufficient to counteract its inotropic benefits, and CO may 
fall (Barrington et al., 1995). 
Pellicer et al. recently reported that the long-term prognosis of E use was the same as DOA 
use, and that both were safe (Pellicer et al., 2009). This important study provided an 
additional treatment option for preterm hypotension. 
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5.3 Non-catecholamine inotropic/pressor agents 
5.3.1 Dobutamine 
5.3.1.1 Physiology of dobutamine in preterm hypotension 
Dobutamine is a racemic mixture of 2 isomers, the D-isomer with ǂ1- and ǂ2-adrenergic 
effects and the L-isomer with ǂ1- and ǂ1- adrenergic effects. Dobutamine is predominantly 
inotropic via stimulation of ǂ1 receptors and has a variable effect on blood pressure 
(Hollenberg, 2011). Dobutamine administration results in a variable decrease in total SVR. 
Unlike DOA, dobutamine increases myocardial contractility exclusively through direct 
stimulation of myocardial adrenergic receptors (Noori et al., 2004). 
5.3.1.2 The use of dobutamine for the treatment of preterm hypotension 
At a dose of 2–15 μg · kg-1 · min-1, dobutamine increases CO mainly through augmenting 
stroke volume (Noori et al., 2004; Roze et al., 1993; Bhatt-Mehta and Nahata, 1989).  
5.3.1.3 Adverse effects of dobutamine treatment 
Adverse effects of dobutamine occur at high doses and include increased heart rate. At very 
high doses, dobutamine may increase blood pressure and SVR (Cheung et al., 1999), likely 
due to stimulation of á-receptors (Fig.5 and 6). One study suggested that dobutamine’s 
potential benefit of increased oxygen delivery to the tissues was offset by increased tissue 
metabolic rate (Penny et al., 2001). 
5.3.2 Vasopressin 
5.3.2.1 Physiology of vasopressin in preterm infants 
Vasopressin induces its physiological responses through 4 receptors, V1, V2, V3, and 
oxytocin receptors (OTR) (Holmes et al., 2001). When vasopressin binds to V1 receptors in 
vascular smooth muscle (Va1 receptors), it activates phospholipase C, triggering calcium 
release from intracellular calcium stores (Fig. 2). This results in vasoconstriction and a 
subsequent increase in blood pressure. Activation of V2 receptors in the stomach increases 
intracellular cyclic AMP levels through the mediation of adenylate cyclase and have an anti-
diuretic effect. V3 receptors (also known as V1b receptors) are involved in vasopressin’s 
adrenocorticotropic hormone (ACTH)-stimulating effects. Finally, OTR receptors mediate 
vasopressing’s oxytocic effects on uterine contractility. 
V2 receptors and OTR receptors also have vasodilating effects that are antagonistic to the 
effects of V1 receptors. In addition, V1 receptors and OTR receptors have diuretic effects, 
which are antagonistic to the anti-diuretic effects of V2 receptors. Vasopressin’s effects are 
most adapted to disease-induced changes. 
Previous reports have indicated that blood levels of endogenous vasopressin show a two-
phased response in adults with shock (Holmes et al., 2001; Landry et al., 1997; Morales et al., 
1999). During the initial phase of shock, endogenous vasopressin is released in large 
amounts and reaches high blood levels in order to maintain tissue perfusion. However, its 
concentration in the blood decreases over time. As such, vasopressin may be depleted due to 
its initial release in large amounts. The release of vasopressin from the pituitary gland may 
also be inhibited by NO produced by the vascular endothelium or due to autonomic 
nervous system disorders (Holmes et al., 2001; Landry et.al, 1997; Morales et al., 1999). 
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The effects of the small amounts of exogenous vasopressin may be a result of enhancing the 
effects of catecholamines, inhibiting inducible NO synthase (iNOS), inhibiting increased 
cGMP induced by NO and ANP, or inactivating KATP channels in vascular smooth muscles 
(Fig.2) (Landry et al., 2001; Hamu et al.,1999). 
In preterm infants, the levels of vasopressin were high during the first 24 hours following 
birth (Ezaki et al., 2009b). The effects of these high levels of endogenous vasopressin on the 
cardiovascular system are not fully understood. 
5.3.2.2 The use of vasopressin for the treatment of hypotension in preterm infants 
Meyer et al. reported that vasopressin (0.035–0.36 U · kg-1 · hr-1) may be a promising rescue 
therapy for catecholamine-resistant shock in extremely-low-birth-weight infants with acute 
renal injury (Meyer et al., 2006). Similarly, Ikegami et al. found that administration of 
vasopressin (0.001–0.01 U · kg-1 · hr-1) was effective in extremely-low-birth-weight infants 
resistant to treatment with catecholamines and steroids (Ikegami et al., 2010). 
5.3 Adverse effects of vasopressin treatment 
The side effects of vasporessin include severe cutaneous ischemia, hepatic necrosis, 
neurological deficits, and dysmetria (Meyer et al., 2006; Rodríguez-Nunez et al., 2006; 
Zeballos et al., 2006). Unlike DOA, E, and dobutamine, there are few reports on the side 
effects of vasopressin. Moreover, it is unclear whether its side effects are dose-dependent 
and what the long-term prognoses are. However, vasopressin is a pharmacological agent 
that can be considered for use in patients in whom other drugs are ineffective. 
5.4 Lusitropes 
5.4.1 Physiology of phosphodiesterase-III inhibitors in preterm hypotension 
Phosphodiesterase inhibitors increase intracellular cyclic AMP and thus have inotropic 
effects independent of ǂ-adrenergic receptors. As such, they result in fewer chronotropic 
and arrhythmogenic effects than catecholamines. However, increased cyclic AMP in 
vascular smooth muscle cells can cause vasodilation, thus reducing SVR, which can 
exacerbate hypotension. In addition, this can reduce pulmonary artery pressure. (Chen et 
al.,1997,1998; Kato et al.,1998). Milrinone, a cyclic nucleotide phosphodiesterase-III inhibitor, 
improves contractility and reduces afterload in adults and newborns with cardiac 
dysfunction.  
5.4.2 The use of phosphodiesterase-III inhibitors for the treatment of preterm 
hypotension  
McNamara et al. reported that intravenous Milrinone (0.33–0.99 μg · kg-1 · min-1) 
administration produced early improvements in oxygenation without compromising 
systemic blood pressure in patients with severe persistent pulmonary hypertension 
(McNamara et al., 2006). One randomized clinical trial did not support the use of Milrinone 
(0.75 μg · kg-1 · min-1 for 3 hrs, then 0.2μ g · kg-1 · min-1 until 18 hours after birth) in the 
prevention of low SVC in the early transitional circulation of preterm infants (Paradisis et 
al., 2009).  
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5.4.3 Adverse effects of Milrinone treatment 
Milrinone can cause hypotension and tachycardia (Chang et al., 1995). The long-term effects 
of Milrinone in preterm infants have not been reported. 
5.5 Corticosteroids  
5.5.1 Physiology of corticosteroids 
The adrenal glands are involved in the growth and maturation of fetal organs during 
intrauterine life. In most mammals, a cortisol surge occurs as the full gestational term 
approaches; this triggers increased synthesis of pulmonary surfactant, reduced sensitivity of 
the arteries to prostaglandins, and increased conversion of pancreatic ǃ-cells from T4 to T3 
in the mature liver. These changes allow the fetus to survive in the extrauterine 
environment. There is also a surge in catecholamines produced by the adrenal medulla 
during delivery. This surge also allows adaptation to the extrauterine environment by 
influencing the cardiovascular system, including elevating the blood pressure and 
increasing the heart function, and by influencing glucose metabolism, fat metabolism, and 
water absorption in the lungs (Fisher, 2002). 
The hypothalamic-pituitary-adrenal system in fetuses and neonates has been implicated in 
late-onset circulatory collapse (Masumoto et al., 2008) and in the fetal programming of the 
cardiovascular system. Preterm infants have low adrenal function due to their low levels of 
3ǃ-hydroxysteroid dehydrogenase (HSD) (Mesiano and Jaffe, 1997) and weak 11b-HSD2 
activity (Donaldson et al.,1991). 
Corticosteroids reverse neonatal hypotension by improving capillary-leak syndrome 
(Briegel et al., 1994), potentiating transmembrane calcium currents, increasing ǃ-receptor 
sensitivity to catecholamines, reversing the downregulation of ǃ-receptors, increasing the 
density of ǃ-receptors, and inhibiting NO synthase expression (Prigent et al., 2004). 
5.5.2 The use of corticosteroids in the treatment of preterm hypotension 
Hydrocortisone administration is effective in the treatment of hypotension and vasopressor 
dependence in hypotensive preterm infants. Its clinical benefits include increasing blood 
pressure and decreasing the requirement for vasopressor administration (Higgins et al., 2010). 
Fernandez et al. have reviewed the use of hydrocortisone in the treatment of premature infants 
(Fernandez and Watterberg, 2009). Before initiating therapy with hydrocortisone in extremely 
preterm infants with refractory hypotension, a blood specimen should be analyzed for cortisol 
concentration. Pending that result, an initial dose of 1 mg/kg can be administered. If the blood 
pressure improves within 2 to 6 h, 0.5 mg/kg can be administered every 12 h (approximately 
8–10 mg/m2 per day). This long dosing interval is used, because hydrocortisone has a longer 
half-life in immature infants (Watterberg et al., 2005). This dosing strategy increases serum 
values by an average of 5 μg/100 ml; higher doses are associated with very high serum 
concentrations. If the initial cortisol concentration is high (>15–20 μg/100 ml), drug 
administration may be discontinued, especially in the absence of a clinical response. 
5.5.3 Adverse effects of corticosteroid treatment 
Although corticosteroid therapy improves blood pressure and circulation, there are many 
potential complications, including spontaneous gut perforation, hyperglycemia, and 
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hypertension and long-term consequences, including cerebral palsy and intellectual 
impairment. These complications necessitate the judicious use of corticosteroids to support 
blood pressure in preterm infants (Yeh et al., 2004).  
Hydrocortisone therapy administered simultaneously with indomethacin or ibuprofen has 
been associated with acute spontaneous gastrointestinal perforation in extremely preterm 
infants. Therefore, care should be taken to avoid concurrent therapy (Watterberg et al., 2004; 
Peltoniemi et al., 2005). Infants who develop spontaneous perforation often have high 
endogenous cortisol concentrations (Watterberg et al., 2004; Peltoniemi et al., 2005).  
Watterberg et al. reported that early, low-dose hydrocortisone treatment was not associated 
with an increased risk of cerebral palsy. In fact, infants treated with hydrocortisone 
displayed improved developmental outcomes. Together with the short-term benefits, these 
data support the use of hydrocortisone for the treatment of adrenal insufficiency in 
extremely premature infants (Watterberg et al., 2007). 
6. Conclusion 
The major findings of the present chapter summarized in the following figure (Fig.8). 
 
Fig. 8. Evaluation and treatment of hypotension in premature infants 
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